Original research
par
Korthuis, P. Todd et al
Date de publication
2022
Géographie
USA
Langue de la ressource
English
Texte disponible en version intégrale
Non
Open Access / OK to Reproduce
Non
Évalué par des pairs
Yes
L’objectif
Opioid agonist medications for treatment of opioid use disorder (OUD) can improve human immunodeficiency virus (HIV) outcomes and reduce opioid use. We tested whether outpatient antagonist treatment with naltrexone could achieve similar results.
Constatations/points à retenir
Supportive, but not conclusive, evidence that HIV clinic-based extended-release naltrexone is not inferior to treatment as usual for facilitating HIV viral suppression. Participants who initiated extended-release naltrexone used less opioids than those who received treatment as usual.
La conception ou méthodologie de recherche
Open-label, non-inferiority randomized trial (n=114)
Mots clés
Outcomes
Illegal drugs
About PWUD
